Integra Lifesciences Holdings (IART) Asset Writedowns and Impairment (2013 - 2025)
Integra Lifesciences Holdings (IART) reported Asset Writedowns and Impairment of $511.4 million for Q2 2025, up 10038.08% on a YoY basis from N/an in Q2 2024, and up 1420358.33% sequentially from $36000.0 in Q4 2024.
Integra Lifesciences Holdings (IART) Asset Writedowns and Impairment (2013 - 2025) Analysis & Trends
Integra Lifesciences Holdings (IART) has 9 years of Asset Writedowns and Impairment data on file, last reported at $511.4 million in Q2 2025.
- For the quarter ending Q2 2025, Asset Writedowns and Impairment rose 10038.08% year-over-year to $511.4 million; the trailing twelve-month figure through Dec 2025 stood at $511.4 million (up 2552.31% YoY), and the FY2025 full-year result was $511.4 million, up 4088.43% from the prior year.
- Asset Writedowns and Impairment rose to $511.4 million in Q2 2025, from $36000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $511.4 million in Q2 2025 to a low of $36000.0 in Q4 2024.
- A 3-year average of $88.9 million and a median of $6.1 million in 2024 frame the typical range for Asset Writedowns and Impairment.
- Peak annual rise in Asset Writedowns and Impairment reached 10038.08% in 2025, while the deepest fall reached 10038.08% in 2025.
- Tracing IART's Asset Writedowns and Impairment over 3 years: stood at $2.8 million in 2021, then slumped by 98.69% to $36000.0 in 2024, then jumped by 1420358.33% to $511.4 million in 2025.
- Business Quant data shows IART's Asset Writedowns and Impairment at $511.4 million in Q2 2025, $36000.0 in Q4 2024, and $7.1 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Integra Lifesciences Holdings | 1.50 Bn | 1.23 Bn | 216.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 511.37 Mn |
| Jun 30, 2025 | 511.37 Mn |
| Dec 31, 2024 | 36,000.00 |
| Dec 31, 2024 | 36,000.00 |
| Sep 30, 2024 | 7.10 Mn |
| Sep 30, 2024 | 7.10 Mn |
| Jun 30, 2024 | 5.04 Mn |
| Jun 30, 2024 | 5.04 Mn |
| Mar 31, 2024 | 7.10 Mn |
| Mar 31, 2024 | 7.10 Mn |
| Mar 31, 2021 | 2.75 Mn |
| Mar 31, 2021 | 2.75 Mn |
| Jun 30, 2019 | 5.80 Mn |
| Jun 30, 2019 | 5.80 Mn |
| Dec 31, 2018 | 41,000.00 |
| Dec 31, 2018 | 41,000.00 |
| Sep 30, 2018 | 4.90 Mn |
| Sep 30, 2018 | 4.90 Mn |
| Sep 30, 2017 | 3.30 Mn |
| Sep 30, 2017 | 3.30 Mn |